Future Market Insights
Search Reports

Cutting Balloons Market

Starting at US$ 5000

Buy Now
Companies
CAGR (2025 to 2035)
5.6%

Cutting Balloons Market Outlook 2025 to 2035

The cutting balloons market is valued at USD 469.9 million in 2025. As per FMI's analysis, the cutting balloons industry will grow at a CAGR of 5.6% and reach USD 810.2 million by 2035.

In 2024, the industry witnessed steady growth, primarily driven by an increase in complex percutaneous transluminal angioplasty procedures across developed and emerging economies. The adoption of cutting balloons was particularly strong in hospitals and specialty cardiovascular centres, where physicians preferred their precise incision capabilities in treating in-stent restenosis and heavily calcified lesions.

North America continued to dominate the industry, accounting for a significant share due to favourable reimbursement policies and increased awareness among healthcare professionals. Meanwhile, the Asia-Pacific region showed early signs of rapid adoption, fueled by improvements in healthcare infrastructure and growing incidences of peripheral artery disease.

Another key trend in 2024 was the technological refinement of cutting balloon catheters, with manufacturers introducing devices featuring enhanced trackability and lower profile designs, enabling easier navigation in complex anatomies. Collaborations between medtech companies and healthcare institutions for clinical trials further contributed to industry momentum.

Looking ahead to 2025 and beyond, the industry is expected to benefit from the aging population, the rise in minimally invasive procedures, and broader access to interventional cardiology treatments. Innovation and geographic expansion are likely to be key growth drivers.

Market Value Insights

Metric Value
Industry Size (2025E) USD 469.9 million
Industry Value (2035F) USD 810.2 million
CAGR (2025 to 2035) 5.6%

The cutting balloons industry is on a steady growth trajectory, driven by the rising demand for minimally invasive cardiovascular procedures. Increasing cases of complex arterial blockages and advancements in balloon catheter technology are fueling adoption across hospitals and specialty clinics. Medical device manufacturers with innovative, low-profile designs stand to gain, while traditional balloon catheter providers may lose share without product upgrades.

Top 3 Strategic Imperatives for Stakeholders

Invest in Next-Gen Cutting Balloon Technology Prioritize R&D to develop lower-profile, highly trackable cutting balloons that cater to complex and calcified lesion cases, ensuring differentiation in a competitive industry.

Align with Minimally Invasive Treatment Trends Expand product portfolios and marketing efforts to align with the global shift toward minimally invasive cardiovascular procedures, particularly in aging populations and emerging economies.

Strengthen Global Distribution and Strategic Partnerships Forge partnerships with hospitals, cardiovascular centres, and local distributors in high-growth regions like Asia-Pacific to expand reach, while considering M&A opportunities to access new technologies or industries.

Risk Probability & Impact
Technological Advancements by Competitors High Probability, High Impact
Regulatory Hurdles and Compliance Delays Medium Probability, High Impact
Economic Downturn Affecting Healthcare Budgets Medium Probability, Medium Impact
Cutting Balloons Market Strategic Imperatives For Stakeholders
Cutting Balloons Market Strategic Imperatives For Stakeholders
Priority Immediate Action
Next-Gen Balloon Prototypes Develop and test cutting balloon prototypes with improved trackability and low profile.
Clinical Trial Initiation Initiate clinical trials to assess performance in complex arterial blockages.
Distribution Partnerships Establish distribution partnerships in emerging industries like Asia-Pacific.

To stay ahead, companies must prioritize innovation in cutting balloon technology, focusing on enhancing catheter precision and minimizing profiles for complex lesions. Expanding clinical trials and establishing strategic partnerships in high-growth regions, especially Asia-Pacific, will be critical for industry penetration.

Furthermore, investing in minimally invasive procedure solutions and aligning with global healthcare trends will position the company as a leader in the evolving cardiovascular industry. This intelligence shifts the roadmap towards accelerating R&D, global distribution, and clinical validation, ensuring the company captures a larger industry share while differentiating from competitors.

Government Regulations and their Impact on Cutting Balloons Market

Countries Regulatory Overview
United States Regulated by FDA; cutting balloons are Class III devices needing Premarket Approval (PMA), clinical trials, and post-market surveillance.
United Kingdom Regulated by MHRA; UKCA marking required post- Brexit. CE marks accepted till mid-2025. Focus on post- industry reporti ng.
France Under ANSM; devices must comply with EU MDR and have CE mark. Emphasis on c linical performance evaluation.
Germany Regulated by BfArM ; CE certification via notified bodies like TÜV. MDR-compliant with focus on safety and traceability.
Italy Requires EU MDR-compliance and CE mark. Products must be registered in national me dical device database (BD/RDM).
South Korea Regulated by MFDS; requires Class III approval, Korean GMP (KG MP), and local representation.
Japan Regulated by PMDA; requires Shonin approval, QMS compliance, and fore ign manufacturer accreditation.
China Regulated by NMPA; Class III status requires local trials, Chin a GMP, and CMDE review.
Australia & NZ Australia’s TGA requires ARTG listing, gradually moving toward local conformity assessments. NZ’s M edsafe aligns closely with TGA.

Cutting Balloons Industry Analyzed Across Top Investment Segments

By Product

Drug-coated cutting balloons are expected to witness the highest growth in the product segment, with a forecasted CAGR of 6.0% between 2025 and 2035. This is mainly due to their capability to directly deliver anti-proliferative drugs to vessel walls, minimizing the use of stents and lowering restenosis rates.

Clinical trials have proven their effectiveness in the treatment of coronary artery disease, resulting in higher adoption by healthcare providers. The synergy between mechanical plaque modification and localized drug delivery makes drug-coated cutting balloons a preferred option in interventional cardiology. By Application:

By Application

In the application segment, Peripheral Artery Disease (PAD) is expected to be the most rapidly growing segment with a forecasted CAGR of 6.2% between 2025 and 2035. Growing prevalence of PAD, along with technological advancements in minimally invasive interventions, has contributed to greater use of cutting balloons for this indication.

Their accuracy in remodeling calcified lesions without extensive vessel trauma makes them well suited to PAD procedures. With growing awareness and diagnosis of PAD worldwide, demand for advanced devices such as cutting balloons is likely to grow enormously, driving industry growth.

End-User

Among the end users, the highest growth is expected in the case of hospitals, at a CAGR of 5.8% for the period from 2025 to 2035. Hospitals are centrally involved in CAD detection, treatment, and management. They offer varied therapies to patients with CAD, including diagnostic intervention, surgery, and rehabilitation activities. Advanced medical technology, experienced cardiologists, and inter-professional teams are all present in ho

Top Cutting Balloons Industry Analysis Across Top Countries

United States

United States sales are forecast to increase at a CAGR of 6.0% between 2025 and 2035. The USA remains the most profitable sector for cutting balloons, aided by an extremely developed interventional cardiology environment and very high rates of percutaneous coronary interventions (PCIs).

Hospitals and cardiac centers are embracing minimally invasive technologies at a fast pace, and cutting balloons are gaining popularity in complex lesion treatment. Favorable reimbursement policies and established R&D presence also contribute to growth. Manufacturer strategic investments and ongoing innovation in balloon design have made the USA a market leader. Growing aging population further drives demand.

United Kingdom

Cutting balloons market in the United Kingdom are expected to grow at a CAGR of 5.4% over the forecast period. The UK market is mature but developing steadily owing to heightened awareness and availability of advanced cardiovascular interventions. The National Health Service (NHS) is focusing on value-based care, resulting in the trend toward precision devices such as cutting balloons for lesion preparation.

In spite of post-Brexit regulatory sophistication, innovation-stimulating policy and cardiovascular disease funding support business momentum. Privatization initiatives and cardiac infrastructure development are influencing higher utilization rates of minimally invasive procedures. Urban areas of England are showing a significant spike in PCI volume.

France

The French market is expected to expand at 5.6% CAGR between 2025 and 2035 in line with overall global averages. France enjoys a growing population and robust public healthcare infrastructure, underpinning steady demand for cardiovascular devices. French cardiac centres and hospitals have high procedural standards, frequently embracing newer devices such as cutting balloons for certain uses like calcified lesions.

Government-backed innovation clusters and collaborations with medtech firms facilitate the launch of advanced devices. The reimbursement scenario continues to be stable, and efforts to debacklog surgery are expected to further drive industry growth, especially in university and tertiary hospitals.

Germany

German sales are estimated to expand at a CAGR of 5.9% till 2035. Germany is a significant interventional cardiology hub in Europe with strong representation of medical device companies and high procedure volume. Balloon cutting is becoming increasingly popular as a result of its effectiveness in complicated plaque modification, and German hospitals often lead the way with their clinical introduction.

Favorable insurance coverage, high healthcare expenditure, and national focus on innovation continue to underpin this development. Medical training and technological acceptance are sophisticated, facilitating quicker clinical adoption. Moreover, demand is increasing beyond city centers to more regional hospitals, making Germany a high-potential sector.

Italy

In Italy sales are expected to grow at a CAGR of 5.5% over the next decade. The Italian industry is gradually embracing cutting balloons as a tool for lesion preparation, particularly in public hospital systems. Growth is supported by government efforts to modernize hospital infrastructure and integrate minimally invasive cardiovascular procedures.

Although there is some variation regionally in availability and expertise, demand is increasing in both northern and southern Italy. Joint programs with European health programs also facilitate training and acquisition of new cardiac technology. Ongoing population aging and rising cardiovascular burden are main drivers of continuous growth.

South Korea

The South Korean industry is poised to grow at a CAGR of 5.2% during the period 2025 to 2035. South Korea is a technologically advanced industry, but the cutting balloon sector is still emerging. Growth is moderate because of price sensitivity and comparatively conservative take-up in public hospitals. But private hospitals and tertiary centres in Seoul and Busan are now starting to embrace cutting-edge instruments for the treatment of complex lesions.

Support from the government for domestic medtech innovation and greater focus on non-invasive cardiology solutions are helping positively. Gradual conversion from conventional balloons to specialty devices such as cutting balloons over the next ten years is likely to gain momentum.

Japan

Industry of cutting balloons in Japan are expected to register a CAGR of 5.0% between the forecast period. Though Japan boasts one of the world's most well-developed healthcare systems, its expansion in the cutting balloon market is slower with a conservative attitude toward new treatments. Its high rate of aging population and high rate of chronic cardiovascular disease make the potential high.

But cost-effectiveness and clinical evidence dominate adoption. Usage is presently focused within specialized cardiology centres and university hospitals. As procedural guidelines are developed and additional clinical evidence increases cutting balloon effectiveness, Japan should see a constant industry adoption.

China

Chinese sales are predicted to expand at a CAGR of 6.4%, the highest among leading industries. Such exceptional growth is initiated by enacting health care reforms, growth in per capita spending on health, and growth of hospital infrastructure. Introduction Cardiovascular disease is now a significant public health issue in China and the government is placing high priority on the capacity-building for interventional cardiology.

The growing availability of competitively priced cutting balloon products by local and foreign manufacturers is expected to drive the demand for cutting balloon devices. The transformation in urbanization and access to tertiary services are driving the growth of procedural volume. The application of new but economical devices has rendered China a significantly profitable prospect for cut balloon manufacturers.

Australia and New Zealand

The industry within Australia and New Zealand is also anticipated to develop at a CAGR of 5.6% until 2035. The region mirrors global patterns with robust health care systems and considerable awareness of cardiovascular risk management. Australia, it discovers, leads the way in minimally invasive cardiac procedures, with New Zealand close on its heels.

The influence of government initiatives to lower cardiac mortality and enhance access to specialist treatment has been seen in device adoption. Advanced hospital systems and positive reimbursement arrangements make it easier to incorporate new technologies like cutting balloons into clinical practice. The industry is comparatively small but high value per case.

Cutting Balloons Industry Players and their Market Share

In the competitive landscape of the cutting balloons industry, top companies adopt various strategies to maintain and grow their industry share. One of the primary strategies is pricing, where companies balance competitive pricing to attract a wide range of customers while ensuring high product quality and profitability.

Innovation is another key approach, with companies heavily investing in research and development to enhance the capabilities of cutting balloons, introducing new features, and improving treatment outcomes. This includes the development of advanced technologies for specialized applications in cardiovascular treatments.

Additionally, companies focus on strategic partnerships, collaborating with healthcare institutions, research organizations, and technology providers to expand their industry reach and diversify product applications. By forming alliances, companies can leverage new technologies, expand their product portfolio, and enter new regional industries.

Moreover, many companies are focusing on geographical expansion, entering emerging industries where the demand for cutting-edge medical devices is rising. This includes mergers, acquisitions, and partnerships that help firms scale operations and strengthen their global presence in key industries. By implementing these strategies, companies aim to stay ahead in a competitive and fragmented industry.

Abbott holds a dominant position in the cutting balloon industry, commanding 21.2% of the total market share. This leadership is attributed to its robust portfolio of interventional devices, with its cutting balloon systems being widely adopted in coronary procedures.

The company’s success is underpinned by strong clinical evidence supporting its products and a well-established global distribution network. Abbott continues to invest in next-generation technologies to address increasingly complex vascular lesions, reinforcing its competitive edge.

Boston Scientific Corporation follows closely with a 21.3% industry share, making it Abbott’s nearest rival. Its Flextome and Wolverine cutting balloon systems have set benchmarks in the industry for precision and control during angioplasty. The company’s recent expansions into emerging markets, along with strategic collaborations with healthcare providers, have further cemented its market presence and widened its reach.

B. Braun Melsungen AG commands a 5.8% share of the market, offering cost-effective vascular intervention solutions. Its SeQuent cutting balloon platform has demonstrated particular traction in European markets. B. Braun’s emphasis on physician training and procedural efficiency helps it maintain a strong competitive position despite the dominance of larger players.

Cook Medical holds 4.5% of the industry share and is known for its specialized devices used in peripheral interventions. The company’s approach centers on delivering tailored solutions for challenging anatomical cases, which has built a loyal base among interventionalists. Steady growth continues through strategic entry into developing healthcare markets.

Cordis accounts for 3.9% of the market, maintaining its legacy in cardiovascular devices. While facing intense competition, Cordis continues to hold relevance by delivering reliable product performance and catering to niche clinical applications within specific vascular territories.

Medtronic possesses an 8.7% market share, leveraging its extensive cardiovascular device portfolio. The company integrates cutting balloon systems into a broader ecosystem that includes imaging and navigation tools, providing physicians with end-to-end solutions for managing complex interventions.

MicroPort Scientific Corporation holds 3.2% of the market, with a rising presence across Asian regions. The company’s strategy focuses on competitive pricing and localized manufacturing, which enables it to gain traction in cost-sensitive markets and expand its footprint steadily.

Opto Circuits (India) Ltd. captures 2.1% of the market, primarily serving the Indian subcontinent and nearby regions. The company benefits from favorable government healthcare initiatives and increasing demand for affordable interventional devices within its domestic market.

Spectranetics, a division of Philips Healthcare, represents 4.3% of the market. The company utilizes Philips’ global healthcare infrastructure to enhance its reach. Its cutting balloon systems are further supported by laser-assisted technologies, providing an edge in treating calcified lesions.

Terumo Corporation holds a 6.5% market share and maintains a strong presence across both coronary and peripheral intervention segments. The company’s consistent performance is bolstered by its global manufacturing capabilities and continued focus on minimally invasive treatment technologies.

Key Companies

  • Abbott
  • Boston Scientific Corporation
  • B. Braun Melsungen AG
  • Cook Medical
  • Cordis
  • Medtronic
  • MicroPort Scientific Corporation
  • Opto Circuits (India) Ltd.
  • Spectranetics (Philips Healthcare)
  • Terumo Corporation
  • TriReme Medical, LLC (QT Vascular Ltd.)
  • Vascular Concepts Limited

Segmentation

By Product:

The industry is segmented into drug-coated, conventional, scoring

By Application:

The industry is divided into coronary artery disease, peripheral artery disease

By End User:

The industry is segmented into hospitals, cardiac centers, ambulatory surgical centers

By Region:

The industry is studied across North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East and Africa

Frequently Asked Questions

What is driving growth in the cutting balloons industry?

Growth is driven by complex angioplasty procedures and technological advancements in cutting balloon catheters.

Which regions are expected to see the highest growth in the cutting balloons industry?

The Asia-Pacific region is growing rapidly, while North America leads due to favourable reimbursement policies.

How is the aging population affecting the cutting balloons industry?

The aging population increases the demand for minimally invasive cardiovascular procedures.

What technological advancements are expected in the cutting balloons industry?

Innovations include lower-profile, highly trackable cutting balloons for complex lesions.

How can companies strengthen their position in the cutting balloons industry?

Companies can focus on R&D, align with minimally invasive trends, and expand through strategic partnerships.

Preview the report firsthand - request a free sample

Get Sample

Get the brochure for pricing and purchase details.

Future Market Insights

Cutting Balloons Market